Skip to content

Study · Animal study (in vivo) · mouse · 2003

6 results

[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].

Barinskiĭ IF, Alimbarova LM, Lazarenko AA, Ataullakhanov RI

Voprosy virusologii1 Sept 2003Cited by 1 (Europe PMC)

PMID14598478 (opens in a new tab)PepBankPUB-14598478
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice infected intraperitoneally with HSV type 2, Gepon at 0.1 and 1 mcg/mouse produced 36% protection.

    In plain wordsIn mice infected with HSV type 2, Gepon produced 36% protection.

    Peptide
    Gepon
    Outcome
    IncreaseProtection against HSV type 2 infection
    Study

    micen: not reported in source

    Intraperitoneal HSV type 2 infection
    Outcome group
    Antiviral activity · Infection
    Studied dose
    0.1 and 1 mcg/mouseAs given in this study (mice).

    Source sentences

    Summary
    "Gepon" possessed the reliable protecting qualities (36% of protection with a mean increase of the infected mouse life by 1.9 days) in experiments with intraperitoneally infected mice (10 LD50/mouse of HSV, type 2), when the drug was administered in doses of 0.1 and 1 mcg/mouse.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice infected intraperitoneally with HSV type 2, Gepon increased mean lifespan by 1.9 days.

    In plain wordsIn mice infected with HSV type 2, Gepon increased average lifespan by 1.9 days.

    Peptide
    Gepon
    Outcome
    IncreaseMean lifespan of infected mice
    Study

    micen: not reported in source

    Intraperitoneal HSV type 2 infection
    Outcome group
    Mortality · Infection
    Studied dose
    0.1 and 1 mcg/mouseAs given in this study (mice).

    Source sentences

    Summary
    "Gepon" possessed the reliable protecting qualities (36% of protection with a mean increase of the infected mouse life by 1.9 days) in experiments with intraperitoneally infected mice (10 LD50/mouse of HSV, type 2), when the drug was administered in doses of 0.1 and 1 mcg/mouse.
  3. 03LabIn vitro (cells)Safety outcome

    In experimental HSV infection studies, Gepon was non-toxic, without a model-specific safety result.

    In plain wordsIn lab and animal HSV infection studies, Gepon was non-toxic, without separate safety results for each model.

    Peptide
    Gepon
    Outcome
    Direction not reportedToxicity
    Study

    n: not reported in source

    HSV types 1 and 2 experimental infection
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug proved to be non-toxic and did not possess any viricidal action.
    1 context sentence
    Summary · context
    Experimental data are reported on the antiviral activity of peptide immune-modulator "Gepon" in infections caused by herpes simplex virus (HSV), types 1 and 2, in vitro and in vivo.
  4. 04LabIn vitro (cells)Activity measurement

    In infected cell culture, preventive Gepon at 6.25 mcg/I produced a maximal 100-fold reduction in viral titer.

    In plain wordsIn cells, preventive Gepon at 6.25 mcg/I reduced the virus amount by up to 100-fold.

    Peptide
    Gepon
    Outcome
    DecreaseViral titer with preventive administration
    Study

    n: not reported in source

    Multiple-infection cell culture
    Outcome group
    Antiviral activity · Infection
    Studied dose
    6.25 mcg/IAs given in this study.

    Source sentences

    Summary
    The maximal effect was a 100-fold reduction of the viral titer when it was used in a concentration of 6.25 mcg/I as a preventive measure 24 hours before triggering the infection.
    1 context sentence
    Summary · context
    Its antiviral effect was registered in experiments with a multiple-infection cells' culture.
  5. 05LabIn vitro (cells)Activity measurement

    In infected cell culture, preventive Gepon had a reliably greater antiviral effect than Gepon given 1 hour after infection onset.

    In plain wordsIn cells, preventive Gepon had a greater antiviral effect than Gepon given 1 hour after infection.

    Peptide
    Gepon
    Outcome
    IncreasePreventive versus therapeutic antiviral effect
    Study

    n: not reported in source

    Multiple-infection cell culture
    Comparator
    Gepon 1 hour after infection onset
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mentioned drug's effect was reliably higher than its use within a treatment scheme (1 hour after the infection onset).
    1 context sentence
    Summary · context
    The maximal effect was a 100-fold reduction of the viral titer when it was used in a concentration of 6.25 mcg/I as a preventive measure 24 hours before triggering the infection.
  6. 06LabIn vitro (cell-free)Activity measurement

    In experimental HSV infection studies, Gepon did not possess viricidal activity.

    In plain wordsIn lab tests, Gepon did not directly inactivate herpes simplex viruses.

    Peptide
    Gepon
    Outcome
    No significant changeViricidal activity
    Study

    n: not reported in source

    Herpes simplex viruses types 1 and 2
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug proved to be non-toxic and did not possess any viricidal action.
    1 context sentence
    Summary · context
    Experimental data are reported on the antiviral activity of peptide immune-modulator "Gepon" in infections caused by herpes simplex virus (HSV), types 1 and 2, in vitro and in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.